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Julia Marschallinger1,2, Iris Scha¨ffner3, Barbara Klein1,2, Renate Gelfert1,2, Francisco J. Rivera1,2, Sebastian Illes1,2,
Lukas Grassner1,2,4, Maximilian Janssen1,2, Peter Rotheneichner1,2,5, Claudia Schmuckermair6, Roland Coras7,
Marta Boccazzi8, Mansoor Chishty9, Florian B. Lagler10, Marija Renic11, Hans-Christian Bauer2,12,
Nicolas Singewald6, Ingmar Blu¨mcke7, Ulrich Bogdahn13, Sebastien Couillard-Despres2,5, D. Chichung Lie3,
Maria P. Abbracchio8 & Ludwig Aigner1,2
As human life expectancy has improved rapidly in industrialized societies, age-related
cognitive impairment presents an increasing challenge. Targeting histopathological processes
that correlate with age-related cognitive declines, such as neuroinﬂammation, low levels of
neurogenesis, disrupted blood–brain barrier and altered neuronal activity, might lead to
structural and functional rejuvenation of the aged brain. Here we show that a 6-week
treatment of young (4 months) and old (20 months) rats with montelukast, a marketed
anti-asthmatic drug antagonizing leukotriene receptors, reduces neuroinﬂammation, elevates
hippocampal neurogenesis and improves learning and memory in old animals. By using gene
knockdown and knockout approaches, we demonstrate that the effect is mediated through
inhibition of the GPR17 receptor. This work illustrates that inhibition of leukotriene receptor
signalling might represent a safe and druggable target to restore cognitive functions in old
individuals and paves the way for future clinical translation of leukotriene receptor inhibition
for the treatment of dementias.
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P
romoting successful ageing is highly relevant, since human
life expectancy has increased rapidly over the past decades.
With increasing age, brain homeostasis changes, cognitive
skills decline and the risk to develop dementia or neurodegen-
erative diseases increases dramatically1. Thus, a major goal of basic
and applied research is to prevent or revert age-related brain
changes responsible for cognitive deﬁcits. Ultimately, this endeavour
aims to maintain or restore cognitive abilities in the elderly in order
to facilitate high quality of life, even in advanced age.
Histopathological hallmarks that correlate with age-related
declines in cognitive function are neuroinﬂammation, in
particular microglia dysfunction, reduced synaptic densities,
blood–brain barrier (BBB) disruption and low levels of
neurogenesis. Concerning neuroinﬂammation, microglia in the
aged brain produce increased levels of pro-inﬂammatory
cytokines such as interleukin (IL)-6, IL-1beta and tumour
necrosis factor (TNF) but also of anti-inﬂammatory cytokines
such as IL-10 and transforming growth factor (TGF) beta1
(refs 2,3). Morphologically, aged microglia have shorter and less
motile processes and larger soma sizes compared with microglia
in young animals4. Also importantly, phagocytosis, one of the
principal microglia functions, seems to be altered in the aged
brain5, and aged microglia exhibit increased expression of
the phagosomal/lysosomal associated marker CD68 (refs 6,7).
The aged brain is further characterized by a declining density
of presynaptic terminals8, as indicated by synaptophysin
immunoreactivity, for example9. Ample evidence of a partially
leaky BBB in the aged brain is demonstrated by greater central
nervous system (CNS) transfer of intravenously injected Evan’s
blue dye in aged compared with young adult rats10, and in
dynamic contrast-enhanced magnetic resonance imaging studies
of aged humans11. Moreover, the rate of adult neurogenesis, that
is, the lifelong generation of new neurons from neural stem and
progenitor cells in the dentate gyrus (DG) in the hippocampus
and in the subventricular zone, decreases dramatically during
ageing in rodents12, and is also reduced in elderly humans13.
Counteracting some, or ideally all, of such age-related changes
might rejuvenate the brain and lead to preservation or even
improvement of cognitive function in the elderly. The feasibility
of such an approach was recently demonstrated by experiments
exposing the aged brain to a young systemic environment, that is,
young blood, through heterochronic parabiosis7,14. The aged
brain responded to young blood by reduced microglia activation,
enhanced neurogenesis, and importantly, by improved cognition.
Vice versa, old blood caused premature ageing of the young brain
and led to impaired cognition. A proteomic approach identiﬁed
eotaxin, a chemokine involved in asthma pathology, as one of the
molecules that is elevated in ageing and that contributes to
neuroinﬂammation, reduced neurogenesis and to impaired
cognition. This triggered us to hypothesize that, aside from
eotaxin, additional mechanisms that are originally related to
peripheral inﬂammatory conditions such as asthma might act or
even be present in the CNS, where they potentially modulate
degenerative and regenerative events.
Leukotriene signalling is well studied in the ﬁeld of asthma.
Leukotrienes mediate inﬂammatory reactions associated with
increased vascular permeability15, and leukotriene receptor
antagonists such as the drug montelukast have been successfully
developed to treat asthmatic patients16. The role of leukotrienes
in the brain, in particular their contribution to degeneration and
regeneration, is less clear and sometimes even controversial17,18.
Nevertheless, elevated levels of leukotrienes were reported in
acute as well as chronic CNS lesions19,20, and also in the aged
brain21, where they might mediate neuroinﬂammatory responses
including microglia activation. Indeed, microglia express the
cysteinyl leukotriene receptor CysLTR1, which mediates pro-
inﬂammatory effects of leukotrienes, and microglia induce the
expression of CysLTR2 and of the leukotriene related GPR17
receptor, for example, after ischaemia22,23. Antagonizing
CysLTR1 and GPR17 with the speciﬁc inhibitor montelukast
reduces the levels of inﬂammatory cytokine expression22–24.
CysLTRs are also expressed on endothelial cells, where they
mediate BBB leakage, and montelukast restores BBB integrity25.
Furthermore, we previously demonstrated leukotriene receptor
expression, in particular GPR17, in adult neurospheres, and
detected a montelukast-induced dose-dependent increase in
progenitor proliferation26. Therefore, montelukast is positioned
to target at least three of the age-related cellular changes in the
brain, that is, microglia activation, BBB integrity and
neurogenesis.
Here, we demonstrate that montelukast reduces neuroinﬂam-
mation, restores BBB integrity and increases neurogenesis
speciﬁcally in the brain of old rats, the latter being mediated
through inhibition of the GPR17 receptor. Most importantly,
montelukast treatment restores cognitive function in the old
animals, paving the way for future clinical translation for the
treatment of dementias.
Results
Montelukast improves learning and memory in old rats. We
analysed the effects of a 6-week oral montelukast (10mg kg 1
body weight) treatment of young (4-months old) and old
(20-months old) rats on learning and memory. Analysis of the
latency times to ﬁnd a hidden platform over 5 consecutive
training days in a Morris water maze test, during which spatial
navigation task learning is typically achieved in young animals,
conﬁrmed that old individuals have learning deﬁcits (Fig. 1a).
Montelukast treatment signiﬁcantly improved task learning in old
rats to a level comparable to young ones, so that on day 5 the
drug-treated old animals found the platform as fast as their young
counterparts. Learning in young animals was not affected by the
drug treatment. Age and treatment groups only differed in the
distances moved, but not in swimming speeds, excluding the
Figure 1 | Montelukast treatment improves learning and memory in old rats. (a) Latency times to ﬁnd the hidden platform in the Morris water maze test
after daily oral administration of 10mg kg 1 montelukast for 6 weeks. (b) Representative tracks of the distances moved in the Morris water maze on day 4
in the different age and treatment groups (scale bar, 50 cm). (c) Swimming speeds of animals in the Morris water maze test. (d–f) Results of probe trial on
day 6: (d) time spent in the former platform quadrant; (e) time spent in zone P, a deﬁned circular area of 20 cm diameter that encloses the former platform
location; (f) number of entries into zone P. (g) Results of the object location memory test (performed on an additional cohort of rats). (h) Body weight of
the animals on days 1 and 42 of treatment. (i) Locomotion as assessed by the distance moved in the open ﬁeld. (j) Anxiety assessed in the elevated plus
maze with analysis of time spent in the closed, centre and open arms. (k) Depression-like behaviour (immobility time in the forced swim test). Data are
shown as mean±s.e.m. (a, c) or mean±s.d. (d–k). * indicates Po0.05; # indicates signiﬁcant differences (Po0.05) compared to young vehicle. Two-way
ANOVA (a,c,h,j), One-way ANOVA (d–f,i,k) with Bonferroni post hoc tests, and the unpaired Student’s t-test (g) were performed. N per group (a–f; h–k): 10
(young vehicle), 10 (young montelukast), 7 (old vehicle), 7 (old montelukast); (g): 5 (old vehicle), 5 (old montelukast). yg veh, young vehicle; yg mtk,
young montelukast; old veh, old vehicle; old mtk, old montelukast.
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latter as a possible cause of different latency times (Fig. 1b,c).
Memory was assessed by removing the platform 1 day after the
last learning session and by analysing the time spent in the former
platform quadrant. For more precise information, we evaluated
the time spent in the former platform location, and assessed the
frequency entering this area. Surprisingly, old rats spent, irre-
spectively of the treatment, a similar amount of time in the for-
mer platform quadrant compared with their young counterparts
(Fig. 1d). However, the old individuals had signiﬁcant deﬁcits in
the ability to remember the exact platform location (Fig. 1e,f)
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suggesting speciﬁc impairments in the precise spatial memory.
Montelukast treatment fully restored these memory impairments
in the old rats, while it did not affect memory in the young
animals (Fig. 1e,f). To explore the broader potential of mon-
telukast in enhancing cognition in ageing, we extended our
analysis and included in a different cohort of 20-months old rats a
spatial discrimination task, the object location memory test. After
changing the position from one of two objects whose original
locations were familiar to the rats, montelukast-treated animals
spent signiﬁcantly more time at the newly positioned object
compared with controls (Fig. 1g). Hence, these data further
support that montelukast treatment leads to improved memory
functions in old individuals. For drug safety reasons, and for the
interest on potential effects of montelukast treatment on non-
cognitive behaviours, we analysed changes in body weight
(Fig. 1h), exploration and locomotion (Fig. 1i), anxiety-like
behaviour (Fig. 1j) and depression-like symptoms (Fig. 1k).
Montelukast treatment did not have any effect on these para-
meters, with the exception of a slight but signiﬁcant increase in
the time spent in the closed arms in the elevated plus maze in
young animals (Fig. 1j), possibly pointing towards a slight
anxiogenic effect of montelukast in the young group. However,
the fact that the times spent in the open arms and in the centre
zone in this test were similar in all groups, points away from an
anxiogenic effect of montelukast.
Since it is reported that the BBB is intact in young animals but
partially leaky in aged individuals, we asked if the age-
dependency of the montelukast effects were due to a differential,
age-related, BBB penetrance of this drug. In this context, we were
also interested in the general brain penetration capacity of
montelukast after oral administration, since so far, only limited
BBB penetration of montelukast has been described27. Thus, we
treated young (4 months) and old (20 months) rats for 1 week
orally with montelukast (10mg kg 1 body weight) and analysed
its presence in serum, brain and cerebrospinal ﬂuid (CSF) by
high-performance liquid chromatography 1 h after the last
montelukast administration. As expected, montelukast was
present in the serum of both young and old rats. Remarkably,
montelukast was, although to a lower level, also detected in the
brain and in the CSF of the treated animals (Supplementary
Fig. 1a). Most importantly, in a human subject taking 10mg per
day montelukast, that is, the approved dose to treat asthma, we
detected montelukast in the serum and in the CSF in a similar
concentration as in the rats (Supplementary Fig. 1a), suggesting
that the standard 10mg per day dose in humans is sufﬁcient to
reach a therapeutic dose in the CSF. In addition, a re-analysis of
the original CNS pharmacology data of montelukast27 indicates a
signiﬁcant BBB penetrance of the drug (Supplementary Fig. 1b).
These data clearly demonstrate that orally administered
montelukast does cross the BBB in a therapeutic dose, and that
age-dependent differential BBB integrity does not affect the
capacity of montelukast to enter the brain.
Montelukast reduces microglia reactivity in old rats. As spatial
learning and memory are strongly associated with hippocampal
function, we concentrated our further histological analyses on this
region. As a measure of neuroinﬂammation, we ﬁrst analysed the
number of Iba1þ microglia, their proliferation index (% of
proliferating cell nuclear antigen (PCNA)þ cells) and their soma
size, the latter being repeatedly used as a surrogate marker for
microglia activation, in particular of phagocytic activity28. The
number of Iba1þ cells and their proliferation index was similar
in all groups (Fig. 2b,c). However, compared with the young age
groups, microglia somata were signiﬁcantly larger in old rats
treated with vehicle only. Importantly, the 6-week montelukast
treatment completely reverted this age-related phenotype, but did
not affect microglia in the young rats (Fig. 2a,d). Next, we
speculated whether the increased microglia soma size in old rats,
as well as its reduction by montelukast, are linked to changes in
phagocytosis. We therefore analysed the expression pattern of
CD68, a protein associated to the phagosomal/lysosomal pathway
of microglia29. Old animals had a signiﬁcant higher number of
Iba1þ microglia co-expressing CD68 (Fig. 2f) and bigger CD68þ
particles (Fig. 2e,g) compared with the young animals, suggesting
altered phagosomal/lysosomal processing of microglia in old rats.
Although montelukast did not inﬂuence the number of Iba1þ /
CD68þ cells in the old age-group, drug treatment led to a
signiﬁcant reduction of the average CD68 particle size in the old
animals. In young animals, neither the number of CD68þ
expressing microglia, nor the average particle size were affected
by montelukast.
Addressing more speciﬁcally the pattern of neuroinﬂammatory
gene expression, we made use of the BV-2 microglia cell line.
First, BV-2 cells showed immunoreactivity for the target receptors
of montelukast, the leukotriene receptor CysLTR1 and the GPR17
receptor (Fig. 2h). Second, we treated BV-2 cells for 24 h with
100 nM of the receptor ligand leukotriene D4 (LTD4), with
15 mM montelukast, or with 100 nM LTD4 together with 15 mM
montelukast, and analysed mRNA expression of inﬂammatory
and anti-inﬂammatory genes (Fig. 2i). A 24-h treatment with
LTD4 led to a signiﬁcant upregulation of the expression of the
pro-inﬂammatory enzyme NOS2. 24 h co-stimulation with
montelukast counteracted this effect and signiﬁcantly reduced
NOS2 mRNA expression. Moreover, in the presence of LTD4
montelukast downregulated the expression of the monocyte-
recruiting cytokine CCL2, whose expression is elevated in
ageing7. Also, mRNA expression of the neuroprotective
cytokine TGF-beta1 was signiﬁcantly elevated after 24 h
treatment with montelukast in the presence of LTD4. In
summary, these ﬁndings further add to the established mode of
action of montelukast as an anti-inﬂammatory drug.
Next, as the BBB is disrupted in neuroinﬂammation and in
ageing30, we analysed BBB integrity using the tight junction
protein claudin-5. Endothelial cells in the hippocampus of young
(4 months) vehicle-treated rats showed strong and continuous
immunostaining with an anti-claudin-5 antibody, illustrating an
intact BBB (Supplementary Fig. 2). In contrast, claudin-5
expression in endothelial cells of old (20 months) vehicle-
treated rats was diffuse and weak, which points toward a
disrupted BBB. The old montelukast-treated rats showed more
intense, more continuous and better-deﬁned endothelial claudin-
5 staining compared with age-matched vehicle controls,
indicating that montelukast improved BBB integrity in old rats.
Montelukast restores hippocampal neurogenesis in old rats.
Further, we investigated if the 6-week treatment with montelukast
had any effects on DG neurogenesis. Proliferation (number of
PCNAþ cells in the subgranular and granular zone) was
approximately three-times lower in old compared with young
animals. Montelukast treatment signiﬁcantly enhanced pro-
liferation, and this effect was speciﬁc for the old individuals
(Fig. 3a). The surplus in PCNAþ cells in the old montelukast-
treated animals was apparently not due to an enlargement of the
neural stem cell pool, as the number of subgranular Sox2þ cells
was unchanged by the drug treatment (Fig. 3b). By contrast, it
was the pool of DCXþ young immature neurons that was
signiﬁcantly expanded by the montelukast treatment (Fig. 3c).
The additional newly generated cells in the old montelukast-
treated rats survived for at least 4 weeks as indicated by the
number of cells that had incorporated BrdU two weeks after onset
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of treatment (Fig. 3d). The effects of montelukast on proliferation
and survival resulted in a signiﬁcant increase of BrdUþ newly
generated cells in the DG of old animals after the 6-week treat-
ment. The fate of the newly generated cells (percentage of BrdUþ
cells co-labelling with NeuN for mature neurons or with GFAP
for astrocytes) was in the expected range of 60–80% neuronal and
B15% glial differentiation and was neither affected by age nor by
treatment (Fig. 2e). As a net result, montelukast treatment
signiﬁcantly increased the number of newly generated neurons in
the DG of old rats (215.97±60.04 BrdUþ /NeuNþ cells) com-
pared with age-matched controls (131.48±44.16 BrdUþ /
NeuNþ cells).
Since ageing is associated with loss of presynaptic terminals8,9
and altered neuronal functionality31, we explored the possibility
that the montelukast-induced effect on cognitive function
was related to these parameters. Indeed, synaptic density
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Iba1þ cells in the DG of young and old montelukast- and vehicle-treated rats. (e) Representative images of CD68þ immunostaining in Iba1þ microglia
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(synaptophysin positive area) was signiﬁcantly reduced in the
hippocampus of old rats, but only slightly and not signiﬁcantly in
the cortex. Montelukast treatment did not restore the synaptic
density in the hippocampus (Supplementary Fig. 3a) implying
that the cognitive improvements in old rats were not related to
changes in synaptic densities in the DG. In the same context, the
6-week montelukast treatment did neither change the DG
immunohistochemical expression pattern of c-Fos, an
immediate early gene and marker for activated neurons
(Supplementary Fig. 3b), nor did montelukast and/or
leukotrienes alter neuronal network activity in rat hippocampal
cultures (Supplementary Fig. 3c–g).
Taken together, montelukast treatment reduced microglia
activation, elevated neurogenesis, and restored cognitive function
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cells stained positively for the respective marker. Pictures illustrate representative images of antibody labelling in the DG of old vehicle and old
montelukast-treated rats. Scale bars, 200mm (a, d), 100 mm (b, c, e). Data are shown as mean±s.d. * indicates Po0.05; # indicates signiﬁcant differences
(Po0.05) speciﬁcally compared with young vehicle. One-way ANOVA with Bonferroni post hoc tests was performed. N per group: 10 (young vehicle), 10
(young montelukast), 7 (old vehicle), 7 (old montelukast). Every tenth section (400mm interval) of one brain hemisphere per animal was analysed. yg veh,
young vehicle; yg mtk, young montelukast; old veh, old vehicle; old mtk, old montelukast; DG dentate gyrus.
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in old rats. Regression and correlation analyses showed that
learning did not correlate with microglial soma size (R2¼ 0.001)
and that the montelukast-induced learning improvement was
independent of the changes in microglia morphology in the old
animals (R2¼ 0.027) (Fig. 4a). In contrast, correlation coefﬁcients
of R2¼ 0.306 for learning/number of PCNAþ cells in the DG,
and of R2¼ 0.225 for learning/number of BrdUþ cells in old
vehicle-treated rats, let rather suggest that the learning success of
old rats might depend on the rate of neurogenesis (Fig. 4b,c).
Moreover, montelukast treatment provoked a stronger correla-
tion between learning and cell proliferation (R2¼ 0.843) and led
to a steeper slope of the regression line, and also strengthened the
correlation between learning/number of BrdUþ cells
(R2¼ 0.601). This might allow the hypothesis that montelukast
not only increases the generation of new neurons but also might
improve the functional use of these neurons.
Leukotriene signalling in the ageing brain. Since montelukast
was developed as a leukotriene receptor inhibitor, we hypothe-
sised that leukotriene production might correlate with the herein
described age-associated brain changes. First, we analysed the
mRNA expression of 5-LOX, the key enzyme in leukotriene
synthesis, in different brain regions of young and old rats.
We found increased levels of 5-LOX mRNA in the neurogenic
regions (hippocampus and subventricular zone), but not in the
cortex, of old rats (Fig. 5a). Age-related elevation of 5-LOX
expression was also evident at the protein level as illustrated by
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Figure 4 | Montelukast-mediated cognitive improvements in old rats correlate with increased neurogenesis. (a) Correlation analysis showed that the
individual learning scores of old vehicle-treated and old montelukast-treated rats were independent of the soma size of Iba1þ cells in the DG (vehicle:
R2¼0.001; y¼ 81.79þ0.034*x; montelukast: R2¼0.027; y¼ 137.35 þ0.368*x). (b) The correlation coefﬁcient between learning success and number of
PCNAþ cells revealed a tendency towards correlation in the old vehicle-treated rats (R2¼0.361; y¼63.75þ0.063*x). Montelukast provoked a stronger
correlation and led to a steeper slope of the regression line (R2¼0.843; y¼80.8þ0.129*x). (c) Similarly, learning and the number of BrdUþ cells showed
a trend for correlation in vehicle-treated old rats (R2¼0.225; y¼ 64.11þ0.111*x), and again, this correlation was strengthened in montelukast-treated rats
(R2¼0.601; y¼ 69.01þ0.261*x). N per group: 6 (old vehicle), 6 (old montelukast). Correlation analysis was performed using the Pearson product
moment correlation test. DG, dentate gyrus.
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Figure 5 | 5-LOX expression is upregulated in the hippocampus of old rats and elderly humans. (a) 5-LOX mRNA expression was signiﬁcantly elevated
within the neurogenic regions (hippocampus: 2.4-fold; SVZ: 1.8-fold) of old (20 months) compared to young (4 months) rats (n¼ 3 per group). (b) 5-LOX
immunoreactivity was strongly increased in the DG of old (’’) compared with young (’) rats. Although in young rats 5-LOX staining was predominately
allocated to granular neurons (’’’), in old rats also Iba1þ microglia (’’’’, arrowheads) expressed 5-LOX. Pictures illustrate representative 5-LOX stainings; ﬁve
rats per group were analysed. (c) In elderly humans (460 years) (’’), intensity of 5-LOX immunostaining in the DG was clearly upregulated compared with
young persons (o35 years) (’) (lower panels show higher magniﬁcations of the dentate gyri depicted in c’,’’). Images in c illustrate the DG of a 27 year old
human person (’), representing the young age group (hippocampi from ﬁve personso35 years analysed), and the DG of a 67-year-old person (’’),
representing 5-LOX expression in the elderly group (hippocampi from ﬁve persons 460 years analysed). Data are shown as mean±s.d.; ** indicates
Po0.01; Student’s unpaired t-test (a). Scale bars, 100mm (b,c). DG, dentate gyrus; HC hippocampus; SVZ, subventricular zone.
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immunohistochemistry. 5-LOX immunoreactivity was more
intense in the hippocampus of old compared with young rats
(Fig. 5b) and was localised to DG granular neurons and to some
microglia (Fig. 5b). Importantly, 5-LOX immunoreactivity was
also strongly enhanced in the DG of elderly humans (460 years)
(Fig. 5c’’) compared with young ones (o35 years) (Fig. 5c’).
Regarding the targets of montelukast, we and others recently
demonstrated CysLTR and GPR17 mRNA expression in adult
neurosphere cultures26,32. Here, we analysed immunoreactivity of
GPR17 and CysLTR1 in the hippocampal DG of old rats (Fig. 6)
and in adult hippocampal neurosphere-derived cells
(Supplementary Fig. 4). GPR17 was localised to progenitors and
mature cells of the oligodendroglial (Olig2, RIP) and neuronal
(DCX, NeuN, betaIII-tubulin) lineage, as well as to some
microglia cells (Iba1). We excluded GPR17 expression in neural
stem cells (subgranular Sox2) and in astrocytes (GFAP). In
contrast, CysLTR1 expression was predominantly observed on
astrocytes (GFAP), on microglia (Iba1) and on some
oligodendroglial cells (Olig2, RIP). CysLTR1 was only rarely
detected on neural stem cells (Nestin, Sox2) and was absent on
cells of the neuronal lineage (DCX, NeuN, betaIII-tubulin).
Hence, both in vitro and in vivo, CysLTR1 expression was
primarily found on non-neuronal cells, while GPR17 was
predominantly present on cells of the neuronal lineage,
suggesting that the montelukast-induced effects on neurogenesis
might most likely be mediated through inhibition of GPR17 and
not CysLTR1.
Since (i) the montelukast-induced improvement in cognition
correlated best with the elevation of neurogenesis, and (ii)
neuronal progenitors and differentiated neurons were devoid of
CysLTR1 but expressed GPR17, we focused the further analysis
on GPR17. It is reported that GPR17 is a target of FoxO
transcription factors, and that GPR17 expression requires
FoxO133. Here, we ﬁrst used FoxO1,3,4ﬂ/ﬂ mouse-derived
neurospheres that were recombined with GFP/Cre retrovirus
and FACS sorted for GFPþ cells to get ﬁrst insight into a
potential role of GPR17 in neurogenesis. We could demonstrate a
drastic reduction of GPR17 mRNA and protein intensity in the
recombined cells compared with control–infected cells (Fig. 7a,b).
Further, in line with our present immunohistochemical
observations and our previously published ﬁndings26, neither
control nor FoxO1,3,4 / neurospheres expressed CysLTR1
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Figure 6 | GPR17 and CysLTR1, target receptors of montelukast, are expressed within the dentate gyrus of old rats. (a–f) GPR17 expression pattern in
the DG of old (20 months) rats. GPR17 immunoreactivity was localised to cells of the oligodendroglial lineage (Olig2þ ), a), to some DCXþ neuronal
progenitors (c), to a subset of NeuNþ granular neurons (d) and to a fraction of Iba1þ microglia (f). GPR17 expression was neither observed in Sox2þ
neural stem cells (b) nor in GFAPþ astrocytes (e). (g–l) CysLTR1 immunoreactivity in the DG of 20-month old rats was localised to a few Sox2þ cells (h),
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Figure 7 | GPR17 knockdown and knockout in neurospheres induce hyperproliferation and abolish the effects of montelukast. (a) GPR17 mRNA
expression in mouse neurospheres derived from adult FoxO1,3,4ﬂ/ﬂ mice and recombined with GPF/Cre retrovirus (FoxO1/3/4 / NPCs), compared with
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neurospheres compared with control neurospheres. (c) Overexpression of FoxO1 by lentiviral transfection upregulated GPR17 mRNA expression in
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neurospheres. (e) In a single-cell neurosphere assay, neural stem cells with FoxO1/3/4 deletion generated signiﬁcantly more neurospheres than control
cells. A 7-day montelukast treatment (10 mM) signiﬁcantly elevated the number of neurospheres in control, but not in FoxO1/3/4 / cells. FoxO1
overexpression decreased neurosphere numbers in vehicle-treated FoxO1/3/4 / NPCs. Montelukast treatment increased the numbers of neurospheres
in FoxO1 transfected FoxO1/3/4 / NPCs compared with vehicle. (f) In neurospheres isolated from adult GPR17 / GFP mice, high numbers of GFPþ
cells are present, indicating active transcription of the GPR17 gene locus in these cells. (g) Optical density (OD) in an MTS assay was 97% increased in
GPR17 / neurospheres compared with wild-type (WT) neurospheres. A 7-day treatment with 10mM montelukast signiﬁcantly elevated OD absorbance
in wild-type NPCs, but did not affect GPR17 / cells. (h) In the single-cell neurosphere assay, neural stem cells from GPR17 / neurospheres generated
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GPR17 / NPCs. Three independent experiments were done in triplicates. Data are shown as mean±s.d. (a,c–e,g,h). * indicates Po0.05, ** indicates
Po0.01. Student’s unpaired t-test (a) and Two-way ANOVA (c–e,g,h) with Bonferroni post hoc tests were performed. Scale bars (b,f), 50mm. MTK,
montelukast; NPC, neuronal progenitor cells; VEH, Vehicle.
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mRNA (Fig. 7a). Importantly, overexpression of FoxO1 by
lentiviral transfection was sufﬁcient to rescue GPR17 expression
and increased its mRNA expression in FoxO1,3,4 deleted
neurospheres to 62% of control levels. In contrast, control
neurospheres did not further upregulate GPR17 mRNA in
response to FoxO1 overexpression (Fig. 7c).
Addressing neuronal progenitor cell (NPC) proliferation in a
neurosphere bulk assay, we observed a six times elevated
expansion rate in FoxO1,3,4 / neurospheres compared with
control neurospheres, which in contrast to the control NPCs, was
not further potentiated by montelukast (Fig. 7d). Overexpression
of FoxO1 in the FoxO1,3,4 deleted cells (which, as described
above, led to upregulation of GPR17 mRNA, Fig. 7c) signiﬁcantly
reduced the expansion rate to a level that was comparable to
control NPCs. Interestingly, FoxO1 transfected FoxO1,3,4 /
neurospheres were susceptible to montelukast treatment and
showed a signiﬁcant increase of cell numbers compared to
vehicle-treatment. In clonal analyses, the percentage of neuro-
sphere-forming cells was signiﬁcantly elevated after FoxO1,3,4
deletion. Moreover, while montelukast treatment elevated the
clonal growth rate of control cells, it did not further affect the
growth of FoxO1,3,4 deleted cells (Fig. 7e). FoxO1 overexpression
in vehicle-treated FoxO1,3,4 / NPCs decreased neurosphere
numbers, and again, these cells reacquired the ability to respond
to montelukast by increased numbers of neurospheres, compared
with vehicle.
Next, to analyse more speciﬁcally the role of GPR17 in neural
progenitor proliferation in vitro, we used neurospheres isolated
from adult GPR17 / GFP mice. GFP expression in a high
number of neurosphere cells indicated transcriptional activity at
the GPR17 gene locus in NPCs (Fig. 7f). We observed a
96% increased basal proliferative activity in an MTS assay in
GPR17 / neurosphere cultures compared with wild-type
neurospheres, and interestingly, in contrast to wild-type cells,
these GPR17 / cells did not respond to montelukast with
enhanced proliferation (Fig. 7g). Similarly, in a single-cell
neurosphere assay, cells from dissociated GPR17 / neuro-
spheres generated more neurospheres than wild-type cells
(P¼ 0.0561; Two-way analysis of variance (ANOVA), Bonferroni
post hoc test), and the increase in neurospheres number induced
by montelukast in wild-type cells was absent in knockout cells
(Fig. 7h). In conclusion, neurospheres with a genetically induced
constraint in GPR17 expression, mediated either through a
FoxO1,3,4 deletion or a direct GPR17 knockout, are released from
growth restriction and do not further respond to montelukast
with enhanced proliferation, suggesting that the montelukast-
induced effect on neurogenesis might indeed be mediated
through inhibition of GPR17.
Discussion
The present work demonstrates that the anti-asthmatic drug and
leukotriene receptor antagonist montelukast restores learning and
memory function in old rats, in which cognition is compromised
as a result of the physiological ageing process. Other general
activities and psychiatric behaviours were not affected by the drug
treatment in the old animals.
Remarkably, montelukast serum levels of the rats used in this
study (young: 288±57.18 ngml 1; old 365±56.45 ngml 1;
Supplementary Fig. 1) were almost identical to the maximum
plasma concentrations in humans after oral administration of the
clinical dose of 10mg montelukast daily (385±85 ngml 1)27,
illustrating that the animals were treated with montelukast in a
dose that pharmacologically resembles the one that is approved
for its use in humans. A critical issue for montelukast to be
developed as a CNS drug is, of course, its CNS pharmacokinetics.
Although montelukast was so far always considered as a drug
with only limited CNS penetration, careful re-analysis of the
original pharmacokinetic report on montelukast27 reveals that
one hour after i.v. drug administration, a substantial amount of
radioactive equivalents of [C14] montelukast (B1/10 of the
plasma levels) had reached the brain (Supplementary Fig. 1b).
Most remarkably, while in plasma (and most other organs, for
example, lung and muscle) montelukast levels strongly decreased
within 24 h, the amount of montelukast in the brain increased. As
a consequence, 24 h after drug injection, montelukast levels in the
brain were even higher than in plasma (Supplementary Fig. 1b),
suggesting the existence of an active transport mechanism for
montelukast through the BBB. Indeed, montelukast is taken up
from the intestine into the blood stream by the organic anion-
transporting polypeptide (OATP)2B1, a transporter that is
expressed also by endothelial cells of brain capillaries34. Also,
the majority (99%) of montelukast in plasma is bound to proteins,
mainly albumin27, providing a BBB transport mechanism as
albumin has been shown to act as a carrier through the BBB35.
The potential of montelukast to enter the CNS is further strongly
supported by our present pharmacokinetic results obtained from
rats (Supplementary Fig. 1a). Strikingly, montelukast was also
detected in the CSF in a human asthma patient, who was on the
approved 10mg per day dose of montelukast, and levels in serum
and CSF were almost identical to the concentrations found in rats
treated with 10mg kg 1 montelukast (Supplementary Fig. 1a).
Entry of montelukast into the CNS is further supported by the
plethora of preclinical data on the effects of systemic montelukast
treatment on brain structure and function. In various animal
models of neurodegenerative diseases, including a model of kainic
acid-induced loss of memory function, an acute Huntintgon’s
disease model of quinolinic acid and malonic acid injection-
induced degeneration of striatal neurons, and a b-amyloid injection
model of Alzheimer’s disease, treatment with montelukast
attenuated behavioural deﬁcits36–38, which was accompanied by
structural brain changes such as inhibition of neuroinﬂammation
and reduced neuronal cell death37,38. Neuroprotective effects of
montelukast have also been demonstrated in animal models of acute
CNS injuries and stroke. For example, in the middle cerebral artery
occlusion model of stroke, pre-treatment with montelukast
signiﬁcantly attenuated neurological deﬁcits, infarct volumes, brain
oedema, loss of neurons and BBB disintegrity39. In a rat model of
spinal cord injury, montelukast treatment resulted in neuro-
protection, reduction of neuroinﬂammation and in improved
motor function40.
Physiological brain ageing is accompanied by the appearance of
speciﬁc histopathological and molecular hallmarks of neuroin-
ﬂammation. For example, the baseline production of pro-
inﬂammatory cytokines like IL-1beta, TNF and IL-6 is increased
and microglia have shortened and less motile processes and an
enlarged cell soma in the brains of aged rodents2–5. Further, aged
microglia are discussed to be impaired in their most important
effector function, that is, phagocytosis5, which is for example
illustrated by an age-dependent accumulation of CD68 immuno-
reactive phagosomal/lysosomal vesicles6,7. Here, we demonstrate
that montelukast reduced age-associated neuroinﬂammation, in
particular microglia activation. Montelukast treatment reduced
the soma size of microglia in old rats, suggesting a less reactive
phenotype. Interestingly, montelukast also reduced the size of
CD68 immunoreactive particles in these aged microglia.
Although the precise function of CD68 is not well understood7,
its accumulation in the aged brain could be interpreted
in the sense that aged microglia either have a higher rate of
phagocytic uptake or a reduced capacity to process the
incorporated material, and importantly, montelukast might
modulate such activities.
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So far, the beneﬁcial functional effects of montelukast in
animal models of neurological diseases have been attributed
almost exclusively to its anti-neuroinﬂammatory action. For
example, montelukast prevented the release of the pro-inﬂam-
matory cytokines IL-1beta and TNF in BV-2 microglia cells and
in primary microglia cultures41. Also, montelukast reduced the
Abeta1–42 injection-induced elevation of pro-inﬂammatory
signalling mediators and cytokines such as NF-kappaB p65,
TNF-alpha and IL-1beta in vivo38. In the present study, we reveal
that montelukast elevated the expression of the anti-
inﬂammatory cytokine TGF-beta1. Moreover, it reduced the
expression levels of NOS2, a pro-inﬂammatory enzyme that is
increased in the ageing CNS5, and of the chemokine and
peripheral monocyte/macrophage chemoattractant CCL2, which
has been identiﬁed in a proteome screen as a blood-derived
ageing factor7. Interestingly enough, these inﬂammatory markers
were reduced to levels even lower than those of untreated controls
or of cells exposed to montelukast alone. This suggests that when
cells are co-stimulated simultaneously, as in the present
experiments, with both LTD4 and montelukast, montelukast
does not merely antagonize the activation induced by LTD4, but
very likely tunes the inﬂammatory systems to differential
responses. This, in turn, indicates that montelukast ‘primes’ the
system towards an anti-inﬂammatory phenotype, and that it does
so preferentially in the presence of pro-inﬂammatory signals
suggesting a rather speciﬁc protective spatio-temporal effect only
where and when inﬂammation is activated.
Alterations of the peripheral innate and adaptive immune
system during ageing are well documented42, and there is
accumulating evidence that the bidirectional crosstalk between
the peripheral immune system and the CNS plays a decisive role
in shaping brain functions43. Age-associated impairments of the
peripheral immune system are under discussion to alter the
highly coordinated interactions between the immune system and
the brain, and to contribute to age-related cognitive declines42.
Since montelukast was originally developed to inhibit peripheral
inﬂammatory reactions in asthmatic patients, and has been
further reported to modulate innate immune cell functions in the
periphery, it is very likely that this drug might, besides its direct
effects on CNS microglia activity, exert a number of anti-
inﬂammatory responses in the CNS indirectly by modulating the
peripheral immune system, for example by downregulating CCL2
in peripheral organs.
Besides its anti-inﬂammatory action, montelukast stabilizes the
BBB, as suggested by the claudin-5 immunohistochemistry
illustrated in the present study. This is further supported by the
literature, as montelukast reduced the inﬁltration of inﬂammatory
cells and BBB permeability in the experimental autoimmune
encephalomyelitis animal model of multiple sclerosis44, decreased
pentylenetetrazol-induced BBB dysfunction25, and reduced BBB
permeability in an animal model of traumatic brain injury45.
Considering the potential of montelukast to restore the BBB, it is
even more important to emphasize that montelukast was detected
in the brain and CSF after oral administration.
Here, we are demonstrating for the ﬁrst time that montelukast
promotes hippocampal neurogenesis, in particular progenitor cell
proliferation, which results in an increased number of newly
generated neurons. The effect on neurogenesis was, like the anti-
inﬂammatory activity, speciﬁc for the old rats. Thus, montelukast
might stimulate neural progenitor proliferation only in situations
in which neurogenesis is compromised. Montelukast might
liberate progenitors from age-associated inhibitory mechanisms,
which most likely include elevated levels of leukotrienes.
Obviously, the extrapolation of these results from normal ageing
to neurodegenerative diseases is intriguing, and some of the
beneﬁcial effects of montelukast in animal models of
neurodegeneration might well be attributed to enhanced
neurogenesis. The fact that montelukast did not stimulate cell
proliferation in the young animals is an important safety feature,
as a hyperstimulation of neural progenitors might increase the
risk to generate brain tumours.
An important issue to address is the mode of action of
montelukast and if the drug-induced improvement in cognition is
mediated through elevation of neurogenesis. Regression and
correlation analyses suggested a causal link between cognition
and neurogenesis in the old rats, and montelukast even fostered
the correlation between neurogenesis and cognition in these
animals. In contrast, learning success showed no correlation with
the anti-inﬂammatory effects of montelukast. Thus, the
montelukast-induced elevated neurogenesis rather than the
anti-inﬂammatory action of montelukast might be the prime
causal factor related to the improved cognition in old rats. This,
however, requires further experimental evidence, for example
through genetic, physical or pharmacological modulation or
inhibition of adult hippocampal neurogenesis. Nevertheless, a
correlation between cognitive performance and DG proliferation
has already been reported previously in aged rodents46.
Moreover, pharmacologic stimulation of neurogenesis by
counteracting age-associated inhibitors of neurogenesis has been
shown to improve cognitive functions in ageing47.
In general, a clear dissection between neurogenesis- and
neuroinﬂammation-mediated effects on cognition is not straight-
forward as neurogenesis and neuroinﬂammation strongly inﬂu-
ence each other. For example neural progenitors induce microglia
proliferation and activation48, and vice versa, microglia regulate
adult hippocampal neurogenesis49. We still lack detailed
knowledge on the exact interrelations between speciﬁc patterns
of neuroinﬂammation and neurogenesis. Pharmacological
modulation of neuroinﬂammation with minocycline altered
hippocampal inﬂammatory cytokine gene expression and
signiﬁcantly improved learning in the water maze paradigm in
aged mice, but did not change the rate of neurogenesis in these
animals, while it elevated neurogenesis without affecting
cognition in young animals50. Hence, the minocycline-induced
effects on cognition in the aged animals appear to be independent
of adult hippocampal neurogenesis modulation. This further
suggests that minocycline and montelukast, although both
being anti-inﬂammatory agents, might address different types of
neuroinﬂammation with speciﬁc consequences on neuro-
protection and regenerative responses such as neurogenesis.
As one of the potential mechanisms of montelukast action, we
identiﬁed elevated leukotriene production in the brains of old rats
and elderly humans, and the montelukast targets CysLTR1 and
GPR17 being expressed in the neurogenic niche. Indeed,
montelukast might interact with CysLTR1 and with GPR17 in
the brain, as we detected montelukast after oral delivery in the
brain parenchyma and in the CSF. Since GPR17 is, besides being
expressed in oligodendroglia, also expressed in the neuronal
lineage, and since genetically mediated reduction of GPR17
(either through deletion of FoxO1,3,4 or through direct knockout
of the GPR17 gene) increased the neural progenitor proliferation
in vitro, we suggest that the effects of montelukast on
neurogenesis and cognition are most likely mediated through
inhibition of GPR17. Indeed, FoxO1,3,4 as well as GPR17
knockout neurospheres did not respond to montelukast in terms
of cell proliferation, and responsiveness in FoxO1,3,4 knockout
cells was rescued through viral mediated expression of FoxO1,
which also restored GPR17 expression. FoxO plays a crucial role
in regulating neural stem cell proliferation and self-renewal, as
FoxO1,3,4 knockout animals show increased brain size and
proliferation of neural progenitor cells during early postnatal life
leading to an exhaustion of the stem cell pool and to low
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neurogenesis in adulthood51. This has been attributed to the
effects of a number of FoxO targets, such as genes that
cooperatively act as soluble inhibitors of the Wnt pathway to
repress Wnt signalling in neural stem cells51. GPR17 signalling
might be one of such FoxO regulated pathways that are involved
in neural stem and progenitor modulation, in particular in the
aged brain. Targeting GPR17 might further be relevant for acute
CNS lesions such as spinal cord injury, since GPR17 has been
identiﬁed in spinal cord ependymal stem cell like cells, and the
in vivo knockdown of GPR17 by antisense oligonucleotides in a
spinal cord injury model reduced tissue damage and motor
deﬁcits52.
What are the upstream signalling components relevant for the
observed montelukast effects? Montelukast is an antagonist of
CysLTR1 and of GPR17, favouring the hypothesis that leuko-
trienes are the relevant ligands that cause neuroinﬂammation and
reduce neurogenesis in the brains of old animals. The leukotriene
signalling pathway is currently under discussion to contribute to
brain inﬂammation associated with age-related dementia and
neurodegenerative diseases18,20. In the CNS, 5-LOX mRNA levels
are elevated in the hippocampus in an Alzheimer’s disease animal
model53 and in the hippocampus of Alzheimer’s disease
patients54. In addition, the concentrations of 5-LOX transcripts
and of leukotrienes are increased speciﬁcally in the hippocampus
of old rodents, as shown in the present work and by others21,55.
Furthermore, intracerebral infusions of LTD4 in adult mice lead
to an accumulation of Ab 1–40 and Ab 1–42 in the hippocampus
and cortex as well as to memory deﬁcits, which could be inhibited
by pre-treatment with the CysLT1R antagonist pranlukast20.
Although leukotrienes mediate and/or exaggerate pathogenesis in
the CNS, it appears that these effects of leukotrienes are context-
dependent. For example, leukotrienes alone did not induce
neuronal cell death in rat cortical neurons in vitro56.
Besides leukotrienes, other ligands and agonists for GPR17 have
been described, which might well contribute to the activation of the
receptor in ageing and in neurodegenerative diseases. For example,
UDP-glucose, which is elevated in the brain after damage,
has been described as GPR17 agonist52, and UDP-glucose
stimulates oligodendroglial progenitor migration and
differentiation by activating GPR17 (ref. 57). Also, oxysterols,
which act as inﬂammatory mediators, have recently been identiﬁed
as potential GPR17 ligands and agonists58. Nevertheless, more
recent studies using GPR17 overexpression in different cell lines
reported that neither UDP-glucose nor leukotrienes were ligands
for GPR17 (refs 59,60), leaving the question of the physiologic
ligands of GPR17 still open for future discoveries.
Similarly, the exact downstream signalling components that
mediate the beneﬁcial effects of montelukast in the old rats are
not fully deciphered at present, and leukotriene receptor-
independent effects cannot be excluded. In this context,
Yagami et al.56 suggested that voltage-gated calcium channels
mediated neuroprotective effects of the leukotriene receptor
antagonist pranlukast in an in vitro model of brain ischaemia.
Moreover, a network-based interference approach has recently
identiﬁed montelukast as a potential inhibitor of dipeptidyl
peptidase-IV, a proteolytic enzyme and target of a number of
approved anti-diabetes drugs which increase the release of
insulin61. Of interest in the context of the present study, such
anti-diabetic drug treatment could attenuate pathogenesis in
animal models of Alzheimer’s disease62, Parkinson’s disease62
and in an animal model of multiple sclerosis63.
In summary, we demonstrate for the ﬁrst time the possibility of
using montelukast to functionally rejuvenate the aged but
otherwise healthy brain. Oral treatment with montelukast
restored learning and memory in old rats, which was signiﬁcantly
impaired in comparison to young animals. Considering the
various beneﬁcial effects of montelukast on CNS functions in
different animal models, this illustrates that leukotriene receptors
and their underlying signalling mechanisms might contribute to
the development of many neurological deﬁcits, and that
montelukast, by targeting these mechanisms, might be able to
modulate and to improve a number of neurological functions in
various CNS diseases.
Methods
Methods that were required to generate Supplementary Data are provided in the
Supplementary Material.
Animals. For the in vivo experiments, young (4 months) and old (20 months) male
transgenic DCX-DsRed2 Fisher 344 rats were used. They express the ﬂuorescent
reporter DsRed2 under control of the neuronal precursor cell-speciﬁc promoter of
the doublecortin (DCX) gene and were originally generated at the transgenic mouse
facility of the University of Heidelberg, Germany, and previously described64. For
all other studies on rat tissue, young (4 months) and old (20 months) male wild-
type Fisher 344 rats (Charles River, Germany) were used. All rats were bred and
housed in the animal facility of the PMU Salzburg under standard conditions of a
12 h light/dark cycle with food and water ad libitum. All animal care and use was in
accordance with the European Community Council Directive (86/609/EEC) and
approved by the Federal State Land Salzburg, Austria (20901-TVG/40/6–2010).
The numbers of rats used to result in statistically signiﬁcant differences were
calculated using G*Power 3.1.7 software. Standard power analyses with a¼ 0.05
and a power of 0.8 were performed to calculate power and sample sizes. For
neurosphere culture experiments, FoxO1/3/4ﬂ mice65 (P56, male, N¼ 6 animals)
were obtained from Ronald A. DePinho (University of Texas MD Anderson
Cancer Center, Houston, US) and GPR17 / GFP mice66 (2 months old, male,
N¼ 10 animals) were provided by Douglas Fields (NICHD, Bethesda, USA).
Mouse tissue was collected in conformity with the Austrian Federal Law for
experiments on living animals (TVG2012y2).
Montelukast treatment and BrdU injections. Montelukast sodium powder
(Sigma), dissolved in ethanol for maximum solubility and then further diluted
(1:9 ratio) with a 0.9% saline (NaCl) solution, was administered daily per oral
gavage (p.o.) at a dose of 10mg kg 1 of body weight for 42 days to young adult
(4 months) and old (20 months) rats (N¼ 7–10 rats/group). Age-matched control
rats received oral gavage of the vehicle solution (10% ethanol in 0.9% NaCl). For
the analysis of cell survival and cell differentiation, all rats received intra-peritoneal
injections of BrdU (Sigma) at 50mg kg 1 of body weight dissolved in 0.9% saline
solution on days 14, 15, 16 and 17. Weight and general appearance of the rats was
recorded daily during the course of the experiment. Criteria for early termination
of treatment were obvious signs of pain, apathy, and loss of weight more than 15%.
During the course of this experiment, one vehicle-treated rat (20 months old) was
killed because of a weight loss of more than 15% for unknown reasons.
Behavioural tests. 28 days after starting the montelukast treatment, several
standardised behavioural tests were carried out. All parameters analysed were
recorded via the use of the video tracking software Ethovision 9.0 (Noldus Infor-
mation Technology).
In the open ﬁeld test (day 29 after the ﬁrst montelukast administration),
spontaneous changes in general locomotor activity were detected. The open ﬁeld
was a black circular plastic plate with a diameter of 1m and a 5 cm high wall, set in
the middle of the testing room. Before a new trial was begun, the open ﬁeld was
cleaned with 70% ethanol. Each rat was placed into the centre of the plate and was
allowed to explore the apparatus for 5min. The total distance moved was recorded.
The elevated plus maze (performed on day 30 after the ﬁrst montelukast
administration) was used to test anxiety of the rats. The wooden maze had four
arms of the same dimensions (50 10 cm) and was situated 50 cm above the ﬂoor.
Two opposite arms were enclosed by 20 cm high opaque walls (closed arms). To
reduce olfactory inﬂuences, the maze was cleaned with 70% ethanol after every
trial. The rats were allowed to perform trials with 10min of free exploration
starting in the central intersection facing an open arm. The camera software
recorded the time spent in the closed arms, in the open arms, and in the centre
zone, and the overall distance moved.
The forced swim test was performed on day 33 to analyse depressive-like
behaviour. Rats were forced to swim for 10min in a square plastic tank (40 cm side
length) ﬁlled to a depth of 30 cm with tap water (20±1 C). During the forced
swimming session, the behaviour was recorded by a video system and scored by a
trained observer, quantifying absolute time measurements. The behaviour of the
animals was assigned to one of the three following behavioural categories: (1)
‘struggling’, deﬁned as movements during which the forelimbs broke the surface of
water; (2) ‘swimming’, deﬁned as movement of the animal induced by movements
of the fore and hind limbs without breaking the water surface; and (3) ‘immobility
time’, deﬁned as the behaviour during which the animal used limb movement just
to keep its equilibrium without any movement of the trunk. After the 10min
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swimming session, animals were gently dried using a towel and returned to their
home cage.
The Morris water maze test (days 35–41) was used to assess the ability of spatial
learning and memory. The apparatus consisted of a circular swimming pool built of
black plastic (170 cm diameter, 30 cm height), ﬁlled with 21 C±1 C tempered
water. The tank was virtually divided into four equal quadrants, with a submerged
hidden 10 10 cm ﬁbreglass platform placed 3 cm below the water surface in the
middle of the target quadrant. The position of the platform was kept unaltered
throughout the learning sessions. In the testing room, several big black cue symbols
were put on each wall for spatial orientation. The water maze task was carried out
twice a day for 5 consecutive days. One day before starting the learning experiment
(day 0), each rat was put into the water and was allowed to locate the submerged
platform for 60 s. If the animal failed to ﬁnd the platform within the 60 s, it was
guided onto the platform and allowed to remain there for 10 s. For the learning
tasks on days 1–5, each rat was put into the water at one of four starting positions,
the sequence of which being selected randomly. In each trial, a ceiling time of 60 s
to ﬁnd the platform was deﬁned. The escape latency time to locate the hidden
platform and the distance moved during the trial were recorded with the camera
software as indices of spatial learning. On day 6, after the learning phase of the
experiment, a probe trial was performed. Here, the platform was removed and each
animal was allowed to explore the pool for 60 s. From the probe trial, several
parameters were recorded as indices of memory: time spent in platform quadrant,
number of crossings of the former platform location, number of crossings of ‘zone
P’ (a deﬁned circular area with 20 cm diameter enclosing the former platform
location) and time spent in zone P.
A learning index was calculated for every rat based on the individual learning
curve obtained in the water maze spatial learning paradigm. For this, the value of
the area under the curve between days 0 and 5 was calculated and subtracted from
300, which represents the value for the worst possible performance. Thus, high
values indicate successful learning, while low learning indices illustrate poor spatial
learning.
For the object location memory test, a test of hippocampus-dependent memory
functions, a different cohort of old (20 months) male Fisher 344 rats was used.
Animals received montelukast and vehicle administration as well as BrdU
injections as described above (N¼ 5 per group), and on days 35–39 of montelukast
treatment, the object location memory test was performed. Prior to training, rats
habituated to the experimental apparatus (a 70 70 40 cm open top plastic box)
for 5min day 1 in the absence of objects for 3 days. During the training period,
rats were placed into the box with two identical objects (beverage cans;
13.5 5.2 cm) and allowed to explore for 15min. During the long-term retention
test, that is, 24 h following the training period, one of the object locations was
shifted and the rats were allowed to explore the experimental apparatus for 10min.
Exploration was scored when a rat’s head was oriented toward the object within a
distance of 2 cm or when the nose was touching the object. The relative exploration
time (t) of the newly positioned object was recorded and expressed as a novelty
index (NI¼ tnovel/(tnovelþ tfamiliar) 100%).
Perfusion and tissue processing. On day 42, all rats were deeply anaesthetized
using a ketamine (20.38mgml 1), xylazine (5.38mgml 1) and acepromazine
(0.29mgml 1) mixture. Transcardial perfusion was performed with 0.9% NaCl
solution, followed by a 4% paraformaldehyde, 0.1M sodium phosphate solution
(pH 7.4). The brains were dissected and post-ﬁxed in the paraformaldehyde
solution overnight at 4 C. Tissues were then cryoprotected in a 30% sucrose
solution. Brains were cut into 40 mm saggital sections using a sliding microtome on
dry ice. Sections were stored at  20 C in cryoprotectant solution (ethylene glycol,
glycerol, 0.1M phosphate buffer pH 7.4, 1:1:2 by volume).
Immunohistochemistry. Free-ﬂoating sections were treated with 0.6% H2O2 in
tris-buffered saline (TBS: 0.15M NaCl, 0.1M Tris-HCl, pH 7.5) for 30min,
followed by three washes with TBS. For immunological detection of PCNA and
BrdU, sections were incubated in 0.3M NaCl/30mM citrate buffer (pH7.0)/ 50%
formamide at 65 C for 2 h, rinsed in 0.3M NaCl/30mM citrate buffer (pH 7.0),
incubated in 2N HCl at 37 C for 30min, rinsed in 0.1M borate buffer (pH 8.5) for
10min and again rinsed in TBS.
All sections were blocked with a solution composed of TBS, 0.1% Triton X-100,
1% bovine serum albumin (BSA), and 0.2% teleostean gelatin (Sigma) for 1 h. This
buffer was also used during the incubation with primary antibodies, which were
applied overnight at 4 C. For chromogenic immunodetection, the sections were
washed extensively and further incubated for 1 h with a biotin-conjugated species-
speciﬁc secondary antibody. Sections were then incubated for 1 h in a peroxidase-
avidin complex solution (Vectastain Elite ABC kit; Vector Laboratories). The
peroxidase activity of immune complexes was revealed with a solution of TBS
containing 0.25mgml 1 3,3 diaminobenzidine (Vector Laboratories), 0.01%
H2O2, and 0.04% NiCl2. The following antibodies and ﬁnal dilutions were used.
Primary antibodies: rat anti-BrdU (1:500, BU1/75, Serotec), rabbit anti-CD68
(1:300, ab125212, Abcam), rabbit anti-CysLTR1 (1:100, SP4109P, Acris), rabbit
anti-Doublecortin (1:300, 4604, Cell Signaling), goat anti-Doublecortin (1:200,
sc-8066, Santa Cruz), mouse anti-5-LOX (1:100, 610695, BD Transduction
Laboratories), guinea pig anti-GFAP (1:500, GP52, Progen), rabbit anti-GPR17
(1:400, 10136, Cayman), rabbit anti-Iba1 (1:300, 019–19741, Wako), goat anti-Iba1
(1:250, ab107159, Abcam), mouse anti-NeuN (1:500, A60, Millipore), goat anti-
Olig2 (1:300, AF2418, R&D Systems), goat anti-PCNA (1:250, C-20, Santa Cruz),
goat anti-Sox2 (1:500, Y-17, Santa Cruz). Secondary antibodies: donkey anti-goat, -
mouse, -rabbit Alexa 488, donkey anti-guinea pig Alexa 568, donkey anti-goat, -
guinea pig, -mouse, -rabbit Alexa 647 (all 1:1000, Invitrogen), donkey anti-rat Cy5,
donkey anti-mouse, -goat, -rabbit, -rat biotinylated (all 1:500, Jackson Immuno
Research). Nuclear counterstaining was performed with 4’, 6’-diamidino-2-
phenylindole dihydrochloride hydrate at 0.25 mgml 1 (DAPI; Sigma). Secondary
antibody controls, in which the ﬁrst antibody was omitted, were performed for all
experiments to ensure speciﬁcity of the antibody staining. Chromogenic
immunodetection was photodocumented using a Zeiss Axioplan microscope
(Zeiss,) equipped with the Zeiss AxioVision imaging system. Epiﬂuorescence
observation was performed on a confocal scanning laser microscope (LSM 710,
Zeiss) with LSM software (ZEN 2011).
Quantitative analysis of immunohistological data. For quantiﬁcation of dif-
ferent cell types in the DG, analyses were performed blinded on coded slides. Every
tenth section (400 mm interval) of one hemisphere was selected from each animal
and processed for immunohistochemistry. To analyse cell proliferation and
survival, PCNA- or BrdU-labelled cells within the DG were counted on a Zeiss
Axioplan microscope. The reference volume of the DG was determined by tracing
the DG area on each analysed section. To estimate the numbers of Sox2þ , DCXþ ,
BrdUþ /NeuNþ , BrdUþ /GFAPþ , Iba1þ , Iba1þ /PCNAþ and Iba1þ /CD68þ
cells in the DG, four randomly selected visual ﬁelds per animal were photographed
using a confocal scanning laser microscope (LSM 710, Zeiss) with LSM software
(ZEN 2011). From these representative pictures, all positively labelled cells were
counted. The corresponding tissue area was measured and multiplied by 40 mm to
obtain the tissue volume. To assess cell densities, the total number of cells counted
was divided by the sample volume and represented as cells per mm3. Because of the
low level of neurogenesis in old animals, in case the total number of BrdU-positive
cells remained below 50, every BrdU-labelled cell detected was examined. For
assessment of possible alterations in the activation state of microglia within the
hippocampus, the soma sizes of the Iba1þ cells within the DG were determined
using the ‘Analyze Particles’ function of ImageJ 1.45 s (ImageJ website: http://
imagej.nih.gov/ij/). For each animal at least 40 microglial cells were assessed. The
‘Analyze Particles’ function of ImageJ was also used to analyse the mean size of
CD68þ particles in four randomly selected visual ﬁelds (maximum projection of
the z-stack across the whole section). For each animal, at least 120 particles were
measured.
Human post-mortem brain tissue. Human hippocampal tissue sections from
autopsy samples of young adult (o35 years, N¼ 5) and elderly (460 years, N¼ 5)
humans with a post-mortem intervalo24 h were used. Human post-mortem tissue
was obtained from the collection of the Department of Neuropathology of the
University Hospital Erlangen (Germany). Written informed consent was obtained
from the patients’ next of kin. The use of these specimen for scientiﬁc purposes was
in accordance with institutional ethical guidelines and was approved by the ethics
committee of the University of Erlangen (Germany). All samples used were
obtained from individuals without any neurological or psychiatric diagnoses. After
tissue extraction, the brain samples were ﬁxed overnight in 10% formalin and
subsequently processed into liquid parafﬁn. All tissue samples were cut at 5 mm on
a rotation microtome and stored at 4 C.
Formalin-ﬁxed parafﬁn-embedded immunohistochemistry. Formalin-ﬁxed
parafﬁn-embedded human tissue sections were deparafﬁnized by incubation in
xylene, rehydrated by a graded series of ethanol and rinsed in distilled water for
5min. For antigen retrieval, the slides were steamed in 0.01M sodium citrate
buffer, pH 6.0 at 100 C for 20min, followed by three washes in TBS. Endogenous
peroxidases were quenched with 0.3% hydrogen peroxide for 20min. Sections were
blocked with a solution composed of TBS, 0.1% Triton X-100, 1% BSA and 0.2%
teleostean gelatin (Sigma) for 20min, and incubated overnight at 4 C with a rabbit
anti-5-LOX antibody (1:50; 610695, BD Pharmingen) diluted in the blocking
solution. After incubation, the sections were washed in TBS, incubated with a
biotinylated rabbit anti-mouse antibody (1:500, Jackson Immuno Research) for 1 h,
washed in TBS, and incubated for 1 h in a peroxidase-avidin complex solution
(Vectastain Elite ABC kit; Vector Laboratories). The peroxidase activity of immune
complexes was revealed with a solution of TBS containing 0.25mgml 1 3,3
diaminobenzidine (Vector Laboratories), 0.01% H2O2, and 0.04% NiCl2. Sections
were mounted with Neo-Mount (Merck).
RNA extraction and quantiﬁcation of 5-LOX mRNA. To detect 5-LOX mRNA
levels in different brain regions of young and old rats, total RNA was extracted
from rat hippocampus, subventricular zone and cortex from 4-month- and
20-month-old Fisher 344 wild-type rats. Animals were decapitated and the tissues
of interest were dissected. Brain samples were homogenized in 1ml of Trizol (TRI
Reagent; Sigma). For phase separation, 200 ml of 1-bromo-3-chloropropane were
added, vortexed and centrifuged (15min at 12,000 g). After transferring the
aqueous phase into a new tube and adding 350ml of ethanol, RNA extraction was
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9466 ARTICLE
NATURE COMMUNICATIONS | 6:8466 |DOI: 10.1038/ncomms9466 | www.nature.com/naturecommunications 13
& 2015 Macmillan Publishers Limited. All rights reserved.
performed using the QIAGEN RNEasy Mini Kit (Qiagen) and cDNA was
synthesized using Promega reverse transcription Kit (Promega).
Quantitative 5-LOX gene expression analysis was performed by the TaqMan
gene expression assay kit (Catalogue number 4369514, Applied Biosystems) and a
speciﬁc validated 5-LOX gene expression assay (Catalogue number
Rn00689111_m1, Applied Biosystems). GAPDH was used as endogenous control
gene for rat 5-LOX quantiﬁcation. The following temperature proﬁle was used:
activation of polymerase 95 C, 10min; 40 cycles of denaturing 95 C, 15 s, and
annealing/extension 60 C, 60 s. Data were obtained with a Rotor-Gene 6000R
Corbett Research (geneXpress) and analysed by delta delta Ct method67.
BV-2 cell culture experiments. Cells from the murine microglial cell line BV-2
(ref. 68) were originally obtained from Banca Biologica e Cell Factory, IRCCS
Azienda Ospedaliera Universitaria San Martino, Genua, Italy, and tested for
mycoplasma contamination (Myco Alert, Lonza) before further use. Cells were
maintained in Dulbecco’s Modiﬁed Eagle’s Medium (Life Technologies)
supplemented with 10% fetal bovine serum and antibiotics (penicillin 100Uml 1,
streptomycin 100Uml 1, HVD Life Sciences) under standard culture conditions
(95% relative humidity with 5% CO2 at 37 C). For RNA expression studies,
subconﬂuent BV-2 cells were treated for 24 h either with 100 nM LTD4 (Sanova
Pharma), 15mM montelukast (Sigma), or with a combination of LTD4 and
montelukast, in which the cells were pretreated with 15 mM montelukast (Sigma)
for 15min before 100 nM LTD4 were added. The controls received only the vehicle
solution (ethanol) for 24 h.
Quantitative gene expression analyses were performed using TaqMan PCR with
reverse transcription technology. RNA was isolated with the RNeasy Mini Plus Kit
(Qiagen) and transcribed to cDNA using the Reverse Transcription System
(Promega) according to the manufacturer’s instructions. Technical duplicates
containing 10 ng of reverse transcribed RNA were ampliﬁed with the GoTAQ
Probe qPCR Master Mix (Promega) using a two-step cycling protocol (95 C for
15 s, 60 C for 60 s; 40 cycles, Bio-Rad CFX 96 Cycler). The following gene
expression assays were employed: Arg-1 (Mm00475988_m1, Applied Biosystems),
CCL2 (Mm.PT.56a.42151692, Integrated DNA Technologies), NOS-2
(Mm00440485_m1, Applied Biosystems), TGFb1 (Mm.PT.56a.11254750,
Integrated DNA Technologies), TNF (Mm00443258_m1, Applied Biosystems) as
well as the following validated housekeepers: HPRT1 (Mm00446968_m1, Applied
Biosystems), PSMD4 (Mm.PT.56.13046188, Integrated DNA Technologies), SDHA
(Mm01352366_m1, Applied Biosystems). Quantiﬁcation analyses were performed
with qBase Plus (Biogazelle) using geNorm algorithms for multi-reference gene
normalization followed by normalization to control conditions.
FoxO1/3/4ﬂ/ﬂ mouse neurospheres. A mouse line with ﬂoxed alleles for FoxO1,
FoxO3 and FoxO4 in FVB/N background was used (FoxO1/3/4ﬂ/ﬂ mice) for the
preparation of neural stem cells. Six male FoxO1/3/4ﬂ/ﬂ mice (P56) were killed via
cervical dislocation and brains were kept in ice-cold PBS. The subependymal zone
was isolated under binocular microscope and kept further in ice-cold PBS. Neural
stem cells were isolated and cultured as described before69. Brieﬂy, cells were
resuspended in Neurobasal (NB) medium (Gibco BRL) supplemented with B27
(Gibco BRL), 2mM L-glutamine (PAN), 100U/ml penicillin/0.1mg l 1
streptomycin (PAN), hereafter referred to as NB/B27. For maintenance and
expansion of the cultures, the NB/B27 was further supplemented with 2 mg/ ml
heparin (Sigma), 20 ng/ml FGF-2 (R&D Systems) and 20 ng/ml EGF (R&D
Systems) (NB-A). Cultures were maintained in T-25 culture ﬂasks at 37 C in a
humidiﬁed incubator with 5% CO2. Passages 2–10 were used througout this study.
For passaging these cells, the culture medium containing ﬂoating neurospheres was
collected in a 15-ml Falcon tube and centrifuged at 120 g for 5min. The pellet
was resuspended in 200 ml of 1% Accutase (PAA) and triturated approximately 10
times using a pipette. Dissociated cells were centrifuged at 120 g for 5min,
resuspended and reseeded.
For retroviral transduction of neural stem cells, mouse neurospheres from
FoxO1/3/4ﬂ/ﬂ mice were passaged and dissociated into single cells as described
above. Cells were counted and resuspended in 2ml culture medium. Virus particles
of a GFP/Cre-Recombinase-expressing retrovirus or an only GFP-expressing
retrovirus corresponding to the number of counted cells were added and the cells
were incubated at 37 C for 30min until the virus particles were inactive. The
transduction was controlled after 4–7 days via ﬂuorescence microscopy. The cells
were FACS sorted to obtain homogenous populations. Knockout of the cells
transduced with the GFP/Cre-Recombinase-expressing retrovirus was controlled
via genotyping. In the following, cells from FoxO1/3/4ﬂ/ﬂ mice that have been
successfully transduced with the GFP/Cre-Recombinase-expressing retrovirus and
that show a FoxO1/3/4 knockout, are termed ‘FoxO1/3/4 / ’ or ‘FoxO1/3/4 KO’.
Overexpression of FoxO1 and rescue of FoxO1/3/4 KO. Both control cells,
which were transduced with a GFP-expressing retrovirus, and FoxO1/3/4 KO cells,
which had been transduced with a GFP/Cre-Recombinase-expressing retrovirus,
were transduced additionally with a lentivirus coding for a dominant active form of
FoxO1 (Lenti-FoxO1-ADA) as described above. This lentivirus was constructed by
cloning the FoxO1-ADA of the pCMV-FoxO1-ADA70 into the expression cassette
of the pLL3.7 lentivirus (Addgene).
For quantitative gene expression analyses, total RNA was isolated from control
and FoxO1/3/4 KO neurospheres (with and without FoxO1 rescue) by using the
RNeasy Mini-Kit (Quiagen) according to the manufacturer’s protocol. Possible
genomic DNA contamination was eliminated by on-column DNAse treatment
using the RNAse-free DNAse-Set according to the manufacturer’s protocol. cDNA
was transcribed using the Fermentas RevertAid First Strand cDNA Synthesis Kit
(Thermo Fisher Scientiﬁc) according to the manufacturer’s instructions.
Quantitative PCR with reverse transcription was performed using the
StepOnePlusTM Real-Time PCR System. Brilliant II Fast SYBR Green quantitative
PCR (qPCR) Master Mix was used for PCR reactions according to the
manufacturer’s protocol. qPCR primers were designed using the software’s Primer3
(http://primer3.sourceforge.net) and NetPrimer (http://www.premierbiosoft.com).
Amplicon sizes ranged from 100–250 bp. Suitability of qPCR primer was analysed
by evaluation of melting curves and by determination of the efﬁciency via a
standard curve. For quantitative expression analysis, the delta delta CT method67
was applied to determine the relative quantity of target sequence using a reference
sample (control) and an endogenous control target sequence. RPL27 was used as
endogenous control target. Primers for qPCR were as follows: RPL27: forward,
CCTGGATAAACTGTGGACATTGG; reverse, TGTAGTAGCCTGATCGAAC
AACA; GPR17: forward, CGACTCACTGGCTTCCTCTT; reverse, GCCAGGTG
AGCATAGAGAGG, CysLTR1: Forward, CCTCTCCGTGTGGTCTATTATGT;
reverse: ACCGGAAAAAGCTCATGGCT.
GPR17 / neurospheres. Neurospheres were obtained from 2-month-old male
GPR17 / GFP mice (N¼ 10), in which the entire GPR17 coding exon is replaced
by an h2bGFP/neo cassette via homologous recombination66. Age-matched
C57BL/6 wild-type mice (N¼ 10) were used as controls. Neurospheres were
isolated and cultured as described for FoxO1/3/4ﬂ/ﬂ mouse neurospheres above.
Passage numbers 2–8 were used throughout this study.
Single-cell cultures—single-cell neurosphere assay. To culture a neurosphere
out of a single neural stem cell, neurospheres were diluted as 1 cell per 25 ml
neurosphere media with 20 ngml 1 growth factors (EGF and FGF-2) with or
without montelukast (10 mM, Sigma), and seeded into the wells of a 60-well Nunc
MicroWell MiniTray (Thermo Scientiﬁc) plate. After seeding the cells, the wells
were examined under a binocular microscope/ﬂuorescent microscope and those
wells that contained one or two cells were marked. After 7 days, the marked
miniwells were examined again under a binocular microscope/ﬂuorescent micro-
scope and the number of formed neurospheres was counted.
Neurosphere bulk assay. A total of 5 104 cells were seeded in a 25-cm2 culture
ﬂask in 5ml medium under proliferative conditions (with 20 ngml 1 EGF and
FGF-2). Montelukast was added to a ﬁnal molarity of 10 mM on days 0, 2, 4 and 6
(control cells received medium only). After 7 days, neurospheres were harvested
and dissociated into single cells. Total numbers of cells were counted and nor-
malized to untreated control cells.
Analysis of cell proliferation—MTS-assay. After passaging, cells were seeded in
96-well culture plates at a concentration of 5 104 cells/ml in a volume of 100ml
NB/B27 medium under proliferative conditions (with 20 ngml 1 EGF and FGF).
The plates were then maintained at 37 C in a humidiﬁed incubator (Heraeus) with
5% CO2 for 7 days. At days 0, 2, 4 and 6, montelukast was added to a ﬁnal molarity
of 10mM to the wells (control cells received medium only). At day 7, proliferation
was assessed using an MTS assay kit (CellTiter 96 AQueous One Solution Cell
Proliferation Assay, Promega) according to the manufacturer’s instructions. After
4 h of incubation, optical density was measured at 490 nm using a plate reader
(Emax Precision Microplate Reader, Molecular Devices).
Adult rat neurosphere cultures. 2–4 month-old female Fischer 344 rats (N¼ 6)
(Charles River) were decapitated and hippocampi were aseptically removed and
dissociated. Neurosphere cultures were obtained as for FoxO1/3/4ﬂ/ﬂ mouse
neurospheres described above. Cultures from passage numbers 2–8 were used
throughout this study.
Immunocytochemistry. For immunocytochemical analysis of BV-2 cells and
mouse neurospheres from FoxO1/3/4ﬂ/ﬂ mice, ﬁxed cells were washed in TBS
(0.15M NaCl, 0.1M Tris-HCl, pH 7.5), then blocked with a solution composed of
TBS, 1% BSA and 0.2% Teleostean gelatin (Sigma) (ﬁsh gelatin buffer, FSGB). The
same solution was used during the incubations with antibodies. Primary antibodies
were applied overnight at 4 C. Fluorochrome-conjugated species-speciﬁc sec-
ondary antibodies were used for immunodetection. The following antibodies and
ﬁnal dilutions were used. Primary antibodies: rabbit anti-CysLTR1 (1:500,
SP4109P, Acris), chicken anti-GFP (1:1,000; GFP1020, Aves Labs) and rabbit anti-
GPR17 (1:400, 10136, Cayman).Secondary antibodies: donkey anti-rabbit Alexa
568, donkey anti-chicken Alexa 647 (all 1:1,000, Invitrogen). Nuclear counter-
staining was performed with 4’, 6’-diamidino-2- phenylindole dihydrochloride
hydrate at 0.25 mg ml 1 (DAPI; Sigma). Specimens were mounted on microscope
slides using a Prolong Antifade kit (Molecular Probes). Epiﬂuorescence observation
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was performed on a confocal scanning laser microscope (LSM 710, Zeiss,) with
LSM software (ZEN 2011).
Statistical analysis. Histological and behavioural experiments were randomized
and performed blinded. Groups were unblinded at the end of each experiment
before statistical analysis. Statistical analyses were performed using the GraphPad
Prism 5.0 software (GraphPad Software) and IBM SPSS Statistics 20 software (IBM
Corporation). Data were tested for normality using the Kolmogorov–Smirnov or
the Shapiro–Wilk test, and equality of variance was conﬁrmed using the F-test.
Means between two groups were compared by the two-tailed unpaired Student’s
t-test or, in case of non-gaussian distribution, by using the two-tailed Mann–
Whitney U-test. Data from multiple groups were analysed by one-way ANOVA,
and two-way ANOVA, followed by the appropriate post hoc tests (as indicated in
the ﬁgure legends) when necessary. Learning index correlation analyses were
performed with the ‘Pearson Product Moment Correlation test’.
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